EQT Life Sciences

EQT Life Sciences is the result of a deliberate platform strategy that brought one of Europe’s longest-running healthcare venture franchises inside the EQT Group. Formerly known as LSP, the firm has a 30-year operating history during which it raised more than EUR 3.0 billion across 12 private funds and supported the development of more than 150 companies before integrating into EQT in 2022. The combined entity now manages roughly EUR 3.5 billion across multiple investment strategies and operates from Amsterdam, Munich and Boston with a deliberately international footprint. For founders, the relevant frame is that EQT Life Sciences combines the discipline and pattern recognition of a multi-decade specialist with the balance sheet and platform support of a USD 200 billion global private capital firm.

The firm’s thesis is built around innovative companies developing therapeutics, medical devices, diagnostics and healthtech globally, with a clear preference for the late-venture and growth stages where capital intensity is high and clinical or commercial inflection is within sight. EQT Life Sciences explicitly targets companies that benefit from European scientific origin and global commercial ambition, and the team has been transparent that it underwrites for meaningful ownership positions and active board engagement rather than passive participation. The firm operates multiple specialized funds targeting different stages and therapeutic areas, with the latest LSP 7 fund continuing the franchise’s late-stage venture mandate. AI is not a primary thesis area in the way it is for digital health specialists, but the firm has selectively backed AI-enabled biology platforms where the underlying drug discovery or device economics are credibly different.

The portfolio reflects the late-venture orientation. Neuravi, the neurovascular intervention company acquired by Johnson and Johnson in 2017, remains one of the franchise’s most cited exits and a clear demonstration of the firm’s medical device thesis. Xeltis, the bioabsorbable implant company, Artios, the DNA damage response biotech, and Tubulis, the antibody-drug conjugate platform, sit across therapeutic devices and drug discovery, with the broader 150-company historical portfolio extending across oncology, neurology, cardiovascular and rare disease. For founders the relevant pattern is that EQT Life Sciences enters at Series B and beyond with conviction-sized checks, follows on aggressively through subsequent rounds and is comfortable being the lead institutional investor through public listing or strategic acquisition.

On stage and check size, the firm operates at Series B, Series C and growth, with initial commitments typically above USD 25 million and meaningful reserves for follow-on participation. EQT Life Sciences is rarely the first institutional check; it is the firm that arrives when a clinical or commercial program needs the capital to reach a regulatory or commercial inflection. For seed and Series A founders the firm is generally not a fit at the initial round, but is worth tracking as a likely participant in subsequent capital events provided the thesis match is clear.

Decision-making sits with a senior team of investment professionals from medical, scientific, business and finance backgrounds. Rene R. Kuijten serves as Head of Fund for LSP 7 and remains one of the most publicly visible partners across the franchise. The firm operates a partnership-led model with deal sponsors taking ownership of portfolio relationships, and the EQT platform integration has added access to operating resources and follow-on capital that the standalone LSP did not have at the same scale.

The most reliable path to engagement is through later-stage syndicate partners. EQT Life Sciences sources extensively from established European venture firms, tier-one US healthcare investors and pharmaceutical strategic investors, and warm introductions from those networks materially shorten the diligence cycle. For Series A founders building toward an eventual Series B, beginning relationship development 12 to 18 months before the round through industry conferences and specialist banker channels is the standard playbook. Cold outreach is rarely effective at this scale.

What founders should know is that EQT Life Sciences is a late-venture specialist with the discipline of a multi-decade franchise and the balance sheet of a global private capital platform, and that its bar for entry is correspondingly high. The firm is unusually transparent about its preference for active board engagement and meaningful ownership, and founders who view those terms as friction will struggle. For European biotech and medtech companies approaching clinical or commercial inflection, EQT Life Sciences remains one of the most credible growth-stage capital partners on the continent.